Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Change in Cash: 2022-2025

Historic Change in Cash for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to $7.7 million.

  • Day One Biopharmaceuticals' Change in Cash fell 95.82% to $7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$379.5 million, marking a year-over-year decrease of 308.99%. This contributed to the annual value of -$105.8 million for FY2024, which is 172.71% down from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Change in Cash of $7.7 million as of Q3 2025, which was up 238.12% from $2.3 million recorded in Q2 2025.
  • Over the past 5 years, Day One Biopharmaceuticals' Change in Cash peaked at $183.1 million during Q3 2024, and registered a low of -$297.8 million during Q4 2024.
  • Over the past 3 years, Day One Biopharmaceuticals' median Change in Cash value was $2.3 million (recorded in 2025), while the average stood at -$3.8 million.
  • Over the last 5 years, Day One Biopharmaceuticals' Change in Cash had its largest YoY gain of 252.43% in 2024, and its largest YoY loss of 2,764.81% in 2024.
  • Quarterly analysis of 4 years shows Day One Biopharmaceuticals' Change in Cash stood at -$35.6 million in 2022, then soared by 70.80% to -$10.4 million in 2023, then crashed by 2,764.81% to -$297.8 million in 2024, then crashed by 95.82% to $7.7 million in 2025.
  • Its Change in Cash stands at $7.7 million for Q3 2025, versus $2.3 million for Q2 2025 and -$91.6 million for Q1 2025.